SCHEMBL6183433

SCHEMBL6183433

CC(C)CC(NC(=O)c1ccc(NC(=O)OCCc2ccccn2)cc1)C(=O)N(C)C#N

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
CTSB P07858 10/20 0.48
CTSL P07711 7/20 0.42
CTSS P25774 6/20 0.42
CTSK P43235 6/20 0.42
SMN1; SMN2 Q16637 4/20 0.40
LMNA P02545 1/20 0.40
RECQL P46063 1/20 0.40
TAS1R3 Q7RTX0 1/20 0.39
TAS1R1 Q7RTX1 1/20 0.39
KDM4E B2RXH2 1/20 0.39
MAPT P10636 1/20 0.39
CTSF Q9UBX1 1/20 0.39
DGAT1 O75907 1/20 0.39
ALDH1A1 P00352 1/20 0.38
USP30 Q70CQ3 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6185987 0.95 CTSB (0.47) NPC1RAB9AMEN1KMT2ACTSB
SCHEMBL6184394 0.92 NPC1 (0.50) NPC1RAB9AMEN1KMT2ACTSB
SCHEMBL6183440 0.85 CTSL (0.59) NPC1RAB9AMEN1KMT2ACTSB
SCHEMBL6182530 0.84 NPC1 (0.53) NPC1RAB9AMEN1KMT2ACTSB
SCHEMBL6184408 0.82 CTSB (0.46) NPC1RAB9ACTSBCTSLCTSS
SCHEMBL6182883 0.81 CTSB (0.55) CTSBCTSLCTSSCTSKTAS1R3
SCHEMBL6183575 0.81 DGAT1 (0.54) NPC1RAB9ACTSBCTSLCTSS
SCHEMBL6183150 0.81 CHRNA7 (0.54) NPC1RAB9AKMT2ACTSBCTSL
SCHEMBL6185989 0.81 CTSL (0.57) NPC1RAB9AMEN1KMT2ACTSB
SCHEMBL6185393 0.79 CTSB (0.47) NPC1RAB9AKMT2ACTSBCTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1161415-B1 N-CYANOMETHYLAMIDES AS PROTEASE INHIBITORS AXYS PHARM INC (US) 2005-07-13 EP disclosed
US-6593327-B2 N-cyanomethyl amides which are cysteine protease inhibitors; treating osteoporosis; mixtures with bisphosphonates AXYS PHARMACEUTICALS, INC. 2003-07-15 US disclosed
US-20030119788-A1 Novel compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2003-06-26 US disclosed
US-6476026-B1 Compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. 2002-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119788-A1 Novel compounds and compositions as protease inhibitors CTRL, SERPINB1, CPN1 NPC1 545/4885RAB9A 2240/4885MEN1 3977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.